MacroGenics | MGNX - Sales Revenues


MacroGenics reported $20.8M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Amgen USD 8.62B 1.28B Mar/2026
AstraZeneca USD 15.29B 213M Mar/2026
Biogen USD 2.25B 30M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Daiichi Sankyo JPY 587B 28.89B Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
Genmab DKK 1.06B 36M Dec/2025
Geron USD 51.84M 3.82M Mar/2026
Gilead Sciences USD 7B 930M Mar/2026
J&J USD 24.1B 500M Mar/2026
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
MacroGenics USD 20.8M 20.43M Mar/2026
Merck USD 16.29B 110M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Roche Holding CHF 15.65B 274.5M Dec/2025
Xencor USD 4.51M 23.73M Mar/2026